Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; and.
Pontificia Universidad Católica de Chile, Santiago, Chile.
Cornea. 2020 Jun;39(6):784-786. doi: 10.1097/ICO.0000000000002262.
To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis.
A retrospective small case series.
The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation.
The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.
报告与使用度普利尤单抗治疗特应性皮炎相关的结膜炎的发生情况。
回顾性小病例系列。
第一个病例是一名 56 岁男性，在开始使用度普利尤单抗 2 周后出现结膜炎。第二个病例是一名 19 岁男性，在开始使用度普利尤单抗 3 个月后出现睑结膜炎。两例患者的眼部炎症均迅速消退，且经局部皮质类固醇滴注治疗得到控制，无需停止使用度普利尤单抗。然而，在就诊时，第二位患者的 1 只眼已出现结膜瘢痕。
对于接受度普利尤单抗治疗特应性皮炎的患者，其发生结膜炎的病理生理学和危险因素尚不完全清楚。然而，局部皮质类固醇治疗可有效抑制炎症，无需停止度普利尤单抗治疗。
